Science Corp., Neurosoft Bioelectronics Form BCI Ecosystem Partnership

Talk about sensical pairings.

Science Corporation and Neurosoft Bioelectronics are teaming up to grant the latter access to Science’s full range of clinical-grade neural recording tools, known as the Science BCI Ecosystem.

Science Ecosystem participants enter into multiyear agreements to develop brain-computer interface (BCI) products around the company’s full neural recording technology stack. Such agreements give partners access to tools for significantly less cost, enabling them to develop products faster than they would otherwise, and consequently, allowing them to focus on their core innovations.

“We recognize that neural engineering breakthroughs happen at the intersection of diverse expertise,” Science Co-Founder/CEO Max Hodak stated. “By providing robust, modular building blocks designed to meet the requirements of the most rigorous modern BCI applications, we are enabling innovation leaders across the BCI industry to develop targeted therapeutic solutions without rebuilding fundamental infrastructure, ultimately bringing transformative therapies to patients faster.”

Neurosoft is developing minimally invasive, fully implantable BCI systems that leverage state-of-the-art soft materials engineering and artificial intelligence to restore function in people with tinnitus, epilepsy, and other disorders. While its technology has already been used in a dozen human patients, the company is now leveraging the Science Ecosystem to eliminate the cost and complexity of custom hardware development.

It can cost upwards of $75 million to $100 million to build a full-stack clinical-grade BCI platform. The Ecosystem partnership gives innovators access to a BCI platform that enables first-in-human trials for under $5 million in a fraction of the time.

“This partnership with Science is a strategic move that aggressively accelerates clinical adoption, bringing potentially life-changing therapies to patients faster than ever seen before in the industry, while rapidly scaling the high-fidelity neural data collection essential for powering Neurosoft’s foundation AI models,” Neurosoft Co-Founder/CEO Nicolas Vachicouras, Ph.D., said.

Known for its PRIMA BCI retina implant, which has been shown in clinical trials to successfully restore vision to patients suffering from certain types of blindness, and for its biohybrid BCI work, Science launched a suite of neural engineering products—the Science BCI Ecosystem—in October 2024 to accelerate innovation and reduce complexity and cost industry-wide.

“Neurosoft is the ideal partner to debut this model,” Science Chief Strategy Officer Darius Shahida commented. “This partnership reflects Science’s broader vision to foster a community of BCI innovators working toward life-changing therapies for neurological injury and disease, and to advance the field by reducing development cost and complexity. Our multiyear, multimillion-dollar agreement is a significant milestone. I fully expect it will be the first of many.”

Science Corporation is a vertically integrated full-stack neural engineering company striving to restore and extend life by transcending the limits of biology. The company is developing advanced brain-computer interface technologies and devices to address critical unmet medical needs and, longer-term, to transform the human condition through neural engineering and advanced perfusion technology. Science is headquartered in Alameda, Calif.

Neurosoft Bioelectronics is a neural data company using ultra-soft interfaces to achieve full-cortical coverage, powering a foundational brain AI model. This visionary leap is enabled by pioneering soft minimally invasive neural implants, which overcome the limitations, stiffness, and risks of traditional rigid electrodes. While the firm’s immediate clinical mission is to deploy these compliant interfaces to safely monitor, treat, and restore lost functions in patients with severe neurological disorders, the data acquired during these life-changing procedures serves a dual purpose. It provides the essential missing data layer, large-scale, high-fidelity neural data with full-cortical coverage required to train a cortical AI model. By leveraging this deep pre-training to translate noisy signals from daily wearables into precise human intent, Neurosoft is bridging the gap between clinical intervention and consumer scalability, ultimately unlocking the future of mass-market, non-invasive, precise, reliable BCIs.